嗜酸粒细胞趋化蛋白-2血清含量对结直肠癌的诊断价值

目的:探讨嗜酸粒细胞趋化蛋白-2（eosinophil chemotactic protein 2,eotaxin 2）的血清含量对结直肠癌的诊断价值。方法:选取2020年1月至2021年2月在江苏大学附属医院胃肠外科就诊的结直肠癌患者50例作为研究对象,另选取同期健康体检者40例作为对照组。酶联免疫吸附实验（ELISA）检测结直肠癌患者及对照组血清中eotaxin-2的含量。分析血清eotaxin-2含量与结直肠癌患者临床病理参数的相关性。绘制受试者工作特征（ROC）曲线并分析血清eotaxin-2对结直肠癌的筛查效能。结果:结直肠癌患者血清中eotaxin-2的含量明显高于健康对照组（Z=-3.93,P<0.01）；血清eotaxin-2含量与结直肠癌患者淋巴转移、远处转移及TNM分期相关（P均<0.01）,而与患者的性别、年龄、肿瘤类型、瘤体大小无明显关系（P均>0.05）；血清eotaxin 2诊断结直肠癌的ROC曲线下面积为0.742（95% CI为0.639~0.845,P<0.01）,诊断敏感性为68.0%,特异性为77.5%。结论:结直肠癌患者血清eotaxin-2含量显著升高,有望成为结直肠癌诊断的生物学标志物。

Diagnostic value of serum eotaxin-2 in colorectal cancer patients

Objective: To detect the expression of eosinophil chemotactic protein 2 (eotaxin-2) in the serum of patients with colorectal cancer (CRC), and investigate its clinical significance. Methods: A total of 50 CRC patients seeking medical care in the Gastroenterology Department of Affiliated Hospital of Jiangsu University from January 2020 to February 2021 were selected as the CRC group, and 40 healthy subjects in the same period were selected as the healthy controls. The serum eotaxin-2 levels were detected by enzyme-linked immunosorbent assay (ELISA). The association between eotaxin-2 level and the clinicopathological features of CRC was analyzed, and the value of serum eotaxin-2 in the diagnosis of CRC was evaluated by the receiver operating characteristic (ROC) curve. Results: The expression level of serum eotaxin-2 was significantly higher in CRC than that in the healthy controls (Z=-3.93, P<0.01). No significant differences were found among the expression levels of serum eotaxin-2 with respect to the gender, age, lesion location and tumor size (all P>0.05), but was significantly correlated with the lymph-node metastasis, distant metastasis and TNM stage (all P<0.01). The area under the ROC was 0.742 (95% CI: 0.639-0.845, P<0.01). The sensitivity and specificity of serum eotaxin-2 for the diagnosis of CRC were 68.0% and 77.5%, respectively. Conclusion: Serum eotaxin 2 level is increased in CRC patients, and may be a candidate biomarker for the CRC diagnosis.